Release No 12/2010
Copenhagen and Oslo, April 23, 2010
Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today
announced that Ferd AS, a shareholder in Affitech, has informed the Company that
it now owns 35,915,472 shares each of nominal value DKK 0.50 representing
35,915,472 voting rights and 7.36% of the outstanding share capital of the
Company
The company further announces that it has today been advised by Braganza AS, a
shareholder in Affitech A/S, that Braganza's ownership of Affitech A/S has now
been reduced below 5% of the outstanding share capital.
The company has one share class.
For more information please contact:
Affitech A/S:
Dr Robert Burns, Chief Executive Officer
Tel # +45 50 99 76 42
Randi Krogsgaard, Corporate Communications
Tel # +45 2310 1001
About Affitech
Affitech AS is a publicly traded (Nasdaq OMX Copenhagen exchange) human
therapeutic antibody company headquartered in Copenhagen, Denmark with R&D
facilities in Oslo, Norway. The company utilizes a range of proprietary antibody
technologies for the discovery of fully human antibodies for application in
oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody
Selection) is Affitech's premier discovery engine for the isolation of lead
antibodies to cell surface molecules in situ. Several of the Company's
proprietary product candidates were generated by CBAS™. Further information is
available at www.affitech.com.
Disclaimer
This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.
No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided herein,
and no claims shall be made by the recipient of this news release by virtue of
the information contained herein.